Do analysts rate RGC or TEVA?

Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 22.11%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Teva Pharmaceutical Industries 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has preferable earnings & valuation, RGC or TEVA?

Teva Pharmaceutical Industries has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Teva Pharmaceutical Industries $17.26B 2.28 $1.41B $1.33 25.72

Do analysts rate RGC or RVMD?

Revolution Medicines has a consensus target price of $123.72, suggesting a potential downside of 17.09%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Revolution Medicines 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 3 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, RGC or RVMD?

Regencell Bioscience has higher earnings, but lower revenue than Revolution Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Revolution Medicines $11.58M 2,739.75 -$1.13B -$7.07 N/A

Is RGC or RVMD more profitable?

Regencell Bioscience's return on equity of 0.00% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Revolution Medicines N/A -83.22% -59.06%

Does the media favor RGC or RVMD?

In the previous week, Revolution Medicines had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 19 mentions for Revolution Medicines and 17 mentions for Regencell Bioscience. Revolution Medicines' average media sentiment score of 0.42 beat Regencell Bioscience's score of 0.01 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate ONC or RGC?

BeOne Medicines presently has a consensus price target of $390.00, suggesting a potential upside of 44.39%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe BeOne Medicines is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.93 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ONC or RGC?

BeOne Medicines has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 5.55 $286.93M $4.47 60.43 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer ONC or RGC?

In the previous week, Regencell Bioscience had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Regencell Bioscience and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.79 beat Regencell Bioscience's score of 0.01 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RGC or BNTX?

BioNTech has a consensus target price of $129.56, indicating a potential upside of 47.10%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNTech 1 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.74

Which has better valuation & earnings, RGC or BNTX?

Regencell Bioscience has higher earnings, but lower revenue than BioNTech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A BioNTech $3.25B 6.86 -$1.29B -$5.88 N/A

Does the media favor RGC or BNTX?

In the previous week, Regencell Bioscience had 9 more articles in the media than BioNTech. MarketBeat recorded 17 mentions for Regencell Bioscience and 8 mentions for BioNTech. BioNTech's average media sentiment score of 0.46 beat Regencell Bioscience's score of 0.01 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RGC or INSM?

Insmed has a consensus price target of $210.50, indicating a potential upside of 123.41%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Insmed 1 Sell rating(s) 0 Hold rating(s) 23 Buy rating(s) 1 Strong Buy rating(s) 2.96

Which has higher earnings and valuation, RGC or INSM?

Regencell Bioscience has higher earnings, but lower revenue than Insmed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Insmed $606.42M 33.68 -$1.28B -$5.75 N/A

Does the media refer more to RGC or INSM?

In the previous week, Insmed had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 21 mentions for Insmed and 17 mentions for Regencell Bioscience. Insmed's average media sentiment score of 0.88 beat Regencell Bioscience's score of 0.01 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Regencell Bioscience (RGC) Competitors

$19.99 -2.17 (-9.79%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$20.25 +0.26 (+1.31%)

As of 06/5/2026 07:58 PM Eastern

Compare

RGC vs. TEVA, RVMD, ONC, BNTX, and INSM

Should you buy Regencell Bioscience stock or one of its competitors? MarketBeat compares Regencell Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regencell Bioscience include Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Regencell Bioscience compare to Teva Pharmaceutical Industries?

Regencell Bioscience (NASDAQ:RGC) and Teva Pharmaceutical Industries (NYSE:TEVA) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Regencell Bioscience has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 22.11%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than Regencell Bioscience. MarketBeat recorded 28 mentions for Teva Pharmaceutical Industries and 17 mentions for Regencell Bioscience. Teva Pharmaceutical Industries' average media sentiment score of 1.22 beat Regencell Bioscience's score of 0.01 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	21 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Teva Pharmaceutical Industries	$17.26B	2.28	$1.41B	$1.33	25.72

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Regencell Bioscience's net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Summary

Teva Pharmaceutical Industries beats Regencell Bioscience on 11 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Revolution Medicines?

Regencell Bioscience (NASDAQ:RGC) and Revolution Medicines (NASDAQ:RVMD) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Revolution Medicines has a consensus target price of $123.72, suggesting a potential downside of 17.09%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

Regencell Bioscience has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Revolution Medicines had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 19 mentions for Revolution Medicines and 17 mentions for Regencell Bioscience. Revolution Medicines' average media sentiment score of 0.42 beat Regencell Bioscience's score of 0.01 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Regencell Bioscience's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Revolution Medicines	N/A	-83.22%	-59.06%

Regencell Bioscience has higher earnings, but lower revenue than Revolution Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Revolution Medicines	$11.58M	2,739.75	-$1.13B	-$7.07	N/A

Summary

Revolution Medicines beats Regencell Bioscience on 9 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

BeOne Medicines has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.55	$286.93M	$4.47	60.43
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

BeOne Medicines presently has a consensus price target of $390.00, suggesting a potential upside of 44.39%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe BeOne Medicines is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Regencell Bioscience had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Regencell Bioscience and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.79 beat Regencell Bioscience's score of 0.01 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Regencell Bioscience's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Regencell Bioscience	N/A	N/A	N/A

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to BioNTech?

Regencell Bioscience (NASDAQ:RGC) and BioNTech (NASDAQ:BNTX) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Regencell Bioscience had 9 more articles in the media than BioNTech. MarketBeat recorded 17 mentions for Regencell Bioscience and 8 mentions for BioNTech. BioNTech's average media sentiment score of 0.46 beat Regencell Bioscience's score of 0.01 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Regencell Bioscience has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. Regencell Bioscience's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
BioNTech	-44.39%	-5.30%	-4.62%

Regencell Bioscience has higher earnings, but lower revenue than BioNTech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
BioNTech	$3.25B	6.86	-$1.29B	-$5.88	N/A

BioNTech has a consensus target price of $129.56, indicating a potential upside of 47.10%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Summary

BioNTech beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Insmed?

Regencell Bioscience (NASDAQ:RGC) and Insmed (NASDAQ:INSM) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Insmed has a consensus price target of $210.50, indicating a potential upside of 123.41%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Regencell Bioscience has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Regencell Bioscience's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Insmed	-144.44%	-130.11%	-51.57%

Regencell Bioscience has higher earnings, but lower revenue than Insmed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Insmed	$606.42M	33.68	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 21 mentions for Insmed and 17 mentions for Regencell Bioscience. Insmed's average media sentiment score of 0.88 beat Regencell Bioscience's score of 0.01 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Insmed beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGC vs. The Competition

Export

Metric	Regencell Bioscience	Medicinal Chemicals Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$9.88B	$5.48B	$4.83B	$12.42B
Dividend Yield	N/A	N/A	8.16%	5.34%
P/E Ratio	N/A	N/A	21.75	23.63
Price / Sales	N/A	0.46	128.53	137.68
Price / Cash	N/A	1.24	52.87	57.17
Price / Book	1,999.00	999.90	27.92	6.35
Net Income	-$3.58M	-$1.41M	$109.80M	$337.59M
7 Day Performance	-16.36%	-16.36%	0.56%	-2.51%
1 Month Performance	-27.55%	-27.55%	0.08%	-0.69%
1 Year Performance	N/A	N/A	12.31%	25.37%

Regencell Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGC Regencell Bioscience	0.16 of 5 stars	$19.99 -9.8%	N/A	N/A	$9.88B	N/A	N/A	10	Trending News
TEVA Teva Pharmaceutical Industries	4.8528 of 5 stars	$32.72 -1.1%	$41.78 +27.7%	+98.5%	$38.04B	$17.26B	24.60	33,950	Trending News Analyst Upgrade
RVMD Revolution Medicines	2.306 of 5 stars	$155.99 +3.1%	$123.72 -20.7%	+271.2%	$32.17B	$11.58M	N/A	250	Analyst Forecast Analyst Revision
ONC BeOne Medicines	4.6156 of 5 stars	$279.00 +1.6%	$390.00 +39.8%	+5.1%	$30.14B	$5.34B	61.45	12,000	Analyst Forecast
BNTX BioNTech	4.0048 of 5 stars	$88.45 -0.8%	$129.56 +46.5%	-20.0%	$22.54B	$3.25B	N/A	7,807	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regencell Bioscience (RGC) Competitors

RGC vs. TEVA, RVMD, ONC, BNTX, and INSM

How does Regencell Bioscience compare to Teva Pharmaceutical Industries?

Summary

How does Regencell Bioscience compare to Revolution Medicines?

Summary

How does Regencell Bioscience compare to BeOne Medicines?

Summary

How does Regencell Bioscience compare to BioNTech?

Summary

How does Regencell Bioscience compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regencell Bioscience (RGC) Competitors

RGC vs. TEVA, RVMD, ONC, BNTX, and INSM

How does Regencell Bioscience compare to Teva Pharmaceutical Industries?

Which has more risk & volatility, RGC or TEVA?

Do analysts rate RGC or TEVA?

Does the media favor RGC or TEVA?

Which has preferable earnings & valuation, RGC or TEVA?

Do insiders & institutionals have more ownership in RGC or TEVA?

Is RGC or TEVA more profitable?

Summary

How does Regencell Bioscience compare to Revolution Medicines?

Do analysts rate RGC or RVMD?

Which has more volatility & risk, RGC or RVMD?

Does the media favor RGC or RVMD?

Do institutionals and insiders hold more shares of RGC or RVMD?

Is RGC or RVMD more profitable?

Which has preferable earnings and valuation, RGC or RVMD?

Summary

How does Regencell Bioscience compare to BeOne Medicines?

Which has higher valuation and earnings, ONC or RGC?

Do analysts rate ONC or RGC?

Does the media prefer ONC or RGC?

Which has more risk and volatility, ONC or RGC?

Is ONC or RGC more profitable?

Do institutionals & insiders have more ownership in ONC or RGC?

Summary

How does Regencell Bioscience compare to BioNTech?

Does the media favor RGC or BNTX?

Do institutionals and insiders believe in RGC or BNTX?

Is RGC or BNTX more profitable?

Which has better valuation & earnings, RGC or BNTX?

Do analysts prefer RGC or BNTX?

Which has more risk and volatility, RGC or BNTX?

Summary

How does Regencell Bioscience compare to Insmed?

Do analysts prefer RGC or INSM?

Is RGC or INSM more profitable?

Which has higher earnings and valuation, RGC or INSM?

Does the media refer more to RGC or INSM?

Which has more risk & volatility, RGC or INSM?

Do institutionals & insiders believe in RGC or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools